Biogen Drops Alzheimer ' s Drug Aduhelm, Ending a 17-year Chapter Biogen Drops Alzheimer ' s Drug Aduhelm, Ending a 17-year Chapter

Biogen will end a post-approval study of Alzheimer ' s treatment Aduhelm and return the licensing rights on the drug after failing to find a partner to mitigate costs of...Reuters Health Information
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Neurology & Neurosurgery Source Type: news